#Canada #Vancouver #Zero Candida #FemTech

Zero Candida, a groundbreaking Israeli FemTech medical device start-up, is excited to announce its full transaction and debut trading on the TSX Venture Exchange under the symbol ZCT, as of November 25th. This milestone marks a significant step forward in the company's journey to revolutionize women's health care through advanced technology. At the heart of Zero Candida's innovation is a smart, tampon-like device that operates on a unique AI-driven therapeutic light source. This device effectively targets Candida fungus with a stunning 99.999% success rate in treating Vulvo-Vaginal Candidiasis (VVC) overnight. VVC is a condition that affects approximately 75% of women globally, impacting millions each year. By harnessing a controlled 'Blue Light' technology, Zero Candida's device promises to eradicate vaginal fungus at a rapid pace without side effects, addressing a critical gap in existing treatment options. The company aims to provide hybrid medical services facilitated by gynecologists, particularly in regions where women lack access to effective treatment, including developing countries. One of the standout features of the ZCT device is its ability to collect and transmit treatment data directly to healthcare providers in real-time. This seamless connectivity, enabled through Wi-Fi and VoIP technology, allows practitioners to assess, personalize, and monitor treatments remotely, making it an invaluable tool for both patients and providers. Eli Ben Haroosh, CEO and Founder of Zero Candida, stated, 'Today marks a milestone for the FemTech industry and women's medical treatments worldwide. Our innovative technology is poised to be a game changer, with the potential for widespread implications in women's health.' The company is currently progressing its research endeavors, aiming to involve hospitals and academic institutions globally. With plans to complete a pre-clinical study by mid-2025 and submit findings to the FDA, Zero Candida is on track to push the boundaries of medical technology and treatment approaches for women's health issues. Alongside developing the treatment device, Zero Candida is committed to expanding access to gynecological care and hybrid medical solutions to underserved populations. This dedication includes ongoing partnerships with medical institutions in Europe and Israel, where pre-clinical agreements have already been signed. Furthermore, safety trials conducted on large animal models, such as sheep, have validated the device's effectiveness and safety profile. Zero Candida's ultimate goal is to finalize its prototype for human use by the first quarter of 2025, marking another critical step toward clinical trials anticipated to take place in June 2025. The company envisions a future where women's health care is advanced through technology, ensuring non-chemical treatment alternatives are accessible and effective. Ben Haroosh added, 'Zero Candida has the potential to become a leader in technological innovation, leveraging our pioneering technology to change the landscape of non-chemical treatments for Candida infections.' As Zero Candida prepares for its public debut, the industry awaits eagerly for what this revolutionary technology has to offer. With women's health care being an imperative subject globally, the ZCT device may very well set a new standard in treatment options moving forward. In conclusion, the launch of Zero Candida on the TSX Venture Exchange is celebrated not just within the company, but across the FemTech sector and the broader health care landscape. With a forward-looking vision and commitment to advancing women's health, Zero Candida stands at the forefront of change, ready to tackle the challenges of VVC and offer hope to millions of women worldwide.